Norepinephrine
Levophed, Ravocaine Novocain W/, Ravocaine Novocain W/ Levophed (norepinephrine) is a small molecule pharmaceutical. Norepinephrine was first approved as Ravocaine and novocain w/ neo-cobefrin on 1982-01-01. It is used to treat hypotension and shock in the USA. The pharmaceutical is active against alpha-2C adrenergic receptor and alpha-2B adrenergic receptor. In addition, it is known to target alpha-1B adrenergic receptor, beta-3 adrenergic receptor, alpha-1A adrenergic receptor, alpha-1D adrenergic receptor, alpha-2A adrenergic receptor, beta-2 adrenergic receptor, beta-1 adrenergic receptor, D(1A) dopamine receptor, and D(1B) dopamine receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Levophed (generic drugs available since 2003-03-03)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levonordefrin
+
Procaine hydrochloride
+
Propoxycaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN | Eastman Kodak | N-008592 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Norepinephrine bitartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | Baxter | N-214313 RX | 2021-01-15 | 2 products, RLD, RS |
| LEVOPHED | Hospira | N-007513 RX | 1982-01-01 | 1 products, RLD, RS |
| NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | InfoRLife | N-215700 RX | 2022-09-15 | 3 products, RLD, RS |
| NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | Long Grove Pharmaceuticals | N-214628 PEND | 2022-10-06 | 3 products, RLD |
Norepinephrine bitartrate
+
Procaine hydrochloride
+
Propoxycaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RAVOCAINE AND NOVOCAIN W/ LEVOPHED | Eastman Kodak | N-008592 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| levophed(r) norepinephrine bitartrate | New Drug Application | 2021-02-05 |
| norepinephrine bitartrate | ANDA | 2023-06-05 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypotension | EFO_0005251 | D007022 | I95 |
| shock | — | D012769 | R57.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Norepinephrine Bitartrate, Norepinephrine Bitartrate In 0.9% Sodium Chloride, Inforlife | |||
| 10888534 | 2039-04-26 | DP | |
| Norepinephrine Bitartrate, Norepinephrine Bitartrate In 0.9% Sodium Chloride, Long Grove Pharms | |||
| 10159657 | 2038-01-30 | DP | |
| 10226436 | 2038-01-30 | DP | U-3461 |
| 10420735 | 2038-01-30 | DP | U-3461 |
| 10568850 | 2038-01-30 | DP | |
| 11413259 | 2038-01-30 | DP | U-3461 |
| 11602508 | 2038-01-30 | DP | |
HCPCS
No data
Clinical
Clinical Trials
57 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 1 | 1 | 1 | 1 | 5 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | — | — | 1 | 2 | 4 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | 1 | 1 | — | 2 |
| Prehypertension | D058246 | — | — | — | 1 | — | 1 | ||
| Hemorrhagic stroke | D000083302 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 3 | — | — | — | 4 |
| St elevation myocardial infarction | D000072657 | — | 1 | — | — | 2 | 3 | ||
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | — | 1 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | 1 | — | — | — | 1 |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | 1 | — | — | — | 1 |
| Leukemia | D007938 | C95 | 1 | 1 | — | — | — | 1 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 1 |
| Lymphoma | D008223 | C85.9 | 1 | 1 | — | — | — | 1 | |
| Depression | D003863 | F33.9 | — | 1 | — | — | — | 1 | |
| Hypotension | D007022 | EFO_0005251 | I95 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vasodilation | D014664 | 2 | — | — | — | 4 | 6 | ||
| Healthy volunteers/patients | — | 2 | — | — | — | 3 | 5 | ||
| Vasoconstriction | D014661 | 3 | — | — | — | 2 | 5 | ||
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | 2 | — | — | — | — | 2 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 2 | — | — | — | — | 2 |
| Heart disease risk factors | D000082742 | 2 | — | — | — | — | 2 | ||
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Pulmonary arterial hypertension | D000081029 | 1 | — | — | — | — | 1 | ||
| Vascular stiffness | D059289 | 1 | — | — | — | — | 1 | ||
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
Show 10 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 2 | 2 |
| Cerebral hemorrhage | D002543 | — | — | — | — | 2 | 2 | ||
| Neoplasms | D009369 | C80 | — | — | — | — | 1 | 1 | |
| Leiomyoma | D007889 | HP_0000131 | D25 | — | — | — | — | 1 | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | — | — | — | 1 | 1 |
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | — | — | 1 | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Lepromatous leprosy | D015440 | EFO_0001057 | A30.5 | — | — | — | — | 1 | 1 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NOREPINEPHRINE |
| INN | norepinephrine |
| Description | (R)-noradrenaline is the R-enantiomer of noradrenaline. It has a role as a vasoconstrictor agent, an alpha-adrenergic agonist, a sympathomimetic agent, a mouse metabolite and a neurotransmitter. It is a conjugate base of a (R)-noradrenaline(1+). It is an enantiomer of a (S)-noradrenaline. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NC[C@H](O)c1ccc(O)c(O)c1 |
Identifiers
| PDB | 3DYE |
| CAS-ID | 51-41-2 |
| RxCUI | 7512 |
| ChEMBL ID | CHEMBL1437 |
| ChEBI ID | 18357 |
| PubChem CID | 439260 |
| DrugBank | DB00368 |
| UNII ID | X4W3ENH1CV (ChemIDplus, GSRS) |
Target
Agency Approved
ADRA2C
ADRA2C
ADRA2B
ADRA2B
Organism
Homo sapiens
Gene name
ADRA2C
Gene synonyms
ADRA2L2, ADRA2RL2
NCBI Gene ID
Protein name
alpha-2C adrenergic receptor
Protein synonyms
adrenergic, alpha-2C-, receptor, Alpha-2 adrenergic receptor subtype C4, Alpha-2C adrenoceptor, Alpha-2C adrenoreceptor, Alpha-2CAR, alpha2-AR-C4
Uniprot ID
Mouse ortholog
Adra2c (11553)
alpha-2C adrenergic receptor (Q01337)
Alternate
ADRA1B
ADRA1B
ADRB3
ADRB3
ADRA1A
ADRA1A
ADRA1D
ADRA1D
ADRA2A
ADRA2A
ADRB2
ADRB2
ADRB1
ADRB1
DRD1
DRD1
DRD5
DRD5
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 110,666 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
156 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more